Physician's Weekly

🎯 #Frailty isn’t just a #transplant risk marker. It may be a treatment target.

Andres Duarte‑Rojo, MD, PhD (@YucaSpice @NUFeinbergMed @NM_Transplant) explains how #LiverTransplant #prehabilitation improved frailty metrics & survival, challenging the idea that patients with frailty must simply endure functional decline while waiting for an organ.

Catch the Q&A👉 bit.ly/4sNMP7o

#MedTwitter

😴 We still diagnose #bipolar depression largely by history. What if physiology could do better?

Julia Maruani, MD, MSc (@hopitalbichat @univ_paris_cite) & team explored how #SleepAnalysis & circadian biomarkers could accelerate diagnosis, reduce misclassification & change the future of mood disorder care. More👉 bit.ly/4yYnoBn

#MedTwitter #PsychX

🦠Is it an #IBD flare, #CDI, or both?

Paul Feuerstadt, MD (@Yale) & team outlined 12 evidence‑based ways to improve care, refine management, and prevent recurrence in this high‑risk population.

For a quick summary, check out this infographic👉 bit.ly/4kzkRdo

#GastroX #MedX

🚨👶Stop benchmarking against average. Benchmark against excellence.

Dr. Elizabeth Alpern (@LurieChildrens @NUFeinbergMed) discusses her research, which analyzed 5.3 MM pediatric #ED visits to identify what top-performing EDs are achieving & where the rest can improve. Q&A👉 bit.ly/4z0U51e

#EmergencyMed #MedX

🔬The biggest impact of #daraxonrasib may be what comes next.

Dr. Deva Mahalingam (@DevaMahalingam @LurieCancer @NUFeinbergMed) discusses why daraxonrasib’s success could redefine future #PancreaticCancer research far beyond a single drug.

🎧Tune in▶️ bit.ly/4z0HFqc

#MedTwitter